Understanding Federal Law Enforcement in the United States Part 6—Drug Enforcement Administration

This is the sixth and final installment in a six-part series examining major federal law enforcement agencies through a research-grounded lens, assessing each agency across the same core categories.

When federal agents dismantle a covert fentanyl lab, when pharmaceutical personnel are charged with unlawful distribution, when investigators trace a methamphetamine pipeline from a Mexican cartel into networks across the U.S., or when the federal government loosens restrictions on the most widely used illegal drug in the country, one agency is at the center of each: the Drug Enforcement Administration (DEA). Yet of the agencies in this series, the DEA is among the least understood as it is often conflated with the broader “war on drugs” rather than recognized for the specific statutory machinery it operates.

The DEA is the federal government’s lead agency for enforcing the nation’s drug laws, and the youngest of the three Department of Justice (DOJ) agencies examined in this series. But its defining feature is that it does not merely enforce the drug laws, it also helps determine which substances are controlled, and how tightly, through its authority over the federal drug-scheduling system. Those scheduling decisions, in turn, help define what counts as a federal drug crime in the first place. It is that combination of powers, enforcing the drug laws while also helping to write them, that has drawn the DEA into one of the most consequential drug-policy debates in a generation: the rescheduling of marijuana, an issue that has reached a turning point in 2026.

Creation and Legislative Origins

Federal drug enforcement as we know it grew out of a particular moment. By the late 1960s, rising drug use, heroin in particular, had become a defining national concern, one that policymakers increasingly tied to street crime and to the addiction of American servicemembers returning from Vietnam. Washington’s response unfolded in two stages. First came a new legal framework, then a single agency to enforce it.

In 1970, Congress enacted the Comprehensive Drug Abuse Prevention and Control Act, whose Title II is the Controlled Substances Act (CSA)—the statute that consolidated federal drug policy into a single framework and established the system of schedules the federal government still uses to classify substances. What the 1970 law did not do was create a unified agency to enforce it.

In June 1971, President Richard Nixon declared drug abuse “public enemy number one” and called for a coordinated, government-wide offensive against it, yet responsibility for enforcing the nation’s drug laws remained scattered across two departments. Most this occurred at the DOJ—the Bureau of Narcotics and Dangerous Drugs and a pair of drug-intelligence and enforcement offices Nixon himself had created—while drug interdiction at the border ran through the U.S. Customs Service, then housed in the Treasury Department. Overlapping missions and rivalry among them, especially between the DOJ’s narcotics agents and Customs, hampered coordination. Seeking a centralized command structure, Nixon used Reorganization Plan No. 2 of 1973, which took effect July 1, 1973, to merge those functions into a single agency. According to the DOJ, the new DEA was formed by combining the BNDD, the DOJ’s existing drug enforcement arm; the Office for Drug Abuse Law Enforcement and the Office of National Narcotics Intelligence; and drug-related elements of the U.S. Customs Service and other federal offices engaged in narcotics work.

The result was an agency built for a single statutory purpose, which was to enforce the CSA nationwide and to coordinate the government’s drug-control activities at home and abroad. By its own account, the DEA traces its institutional lineage back through a series of narcotics bureaus dating to 1930.

Mission

The DEA’s stated mission is to enforce the controlled substances laws and regulations of the United States and to bring to justice the drug-trafficking organizations, from transnational cartels to domestic distribution networks, and the leaders who run them, responsible for producing, smuggling, or distributing controlled substances for the illicit market.

In practice, the DEA wears two hats. As an enforcement agency, its special agents investigate drug-trafficking organizations, run undercover operations and controlled buys, and dismantle distribution networks. As a regulatory agency, its Diversion Control Division registers and oversees the legal pharmaceutical supply chain—the doctors, pharmacies, manufacturers, and researchers authorized to handle controlled substances—and polices the diversion of those legal drugs into illicit channels. That regulatory authority extends to the scheduling system itself. Where a substance falls within that system depends on how dangerous the government judges it to be. This is evaluated based primarily on the drug’s potential for abuse, its capacity to cause dependence, and its risk to public health, weighed against any accepted medical use. By deciding how a substance is classified, the DEA helps determine not only whether it is legal but how its manufacture, distribution, or possession is punished under federal law. It is the same authority implicated in the marijuana debate discussed below.

How the DEA prioritizes its mission has shifted across administrations. Over its half-century of operation, the agency’s enforcement focus has tracked the drugs and markets of the day, and presidents have varied in how they have directed and resourced it. Some have emphasized large-scale interdiction and overseas operations in some periods, and domestic priorities such as curbing the diversion of legal prescription drugs into illicit channels in others. As a result, the agency’s day-to-day responsibilities have often been shaped as much by the policy choices of the administration in charge as by its founding statute.

As earlier installments in this series noted, the same shifting-priorities dynamic reshaped agency deployments in 2025. The DEA was part of a broader, government-wide redirection of federal agents toward immigration enforcement. Early reporting indicated the agency had shifted about a quarter of its work to immigration operations; by later in the year, analyses of internal data put the share closer to half of its agents at points—drawing congressional scrutiny over the resulting strain on counter-narcotics work, with DEA referrals for prosecution falling over the same period. The distance between the DEA’s stated counter-drug mission and how its personnel are deployed is, like the other agencies in this series, is a question successive administrations have answered differently.

Scale

The DEA employs approximately 9,800 personnel, including about 4,650 special agents, and operates on a budget exceeding $3 billion, according to the agency’s most recently published figures. It is headquartered in Arlington, Virginia, across from the Pentagon, and since July 2025 has been led by Administrator Terry Cole, a longtime DEA veteran confirmed by the Senate that month.

Domestically, the agency is organized into 23 divisions overseeing more than 200 offices. Internationally, the DEA maintains more than 90 foreign offices in 68 countries, organized into foreign divisions—one of the largest international footprints of any U.S. law enforcement agency, reflecting the cross-border nature of the drug trade.

Jurisdiction

The DEA derives its authority from the CSA, codified in Title 21 of the U.S. Code. Unlike agencies whose jurisdiction is bounded by geography, the DEA’s reach is defined by subject matter—controlled substances—and extends nationwide and overseas. It shares concurrent jurisdiction over narcotics offenses with the Federal Bureau of Investigation (FBI), as Part 4 of this series discussed, and frequently works alongside state and local partners through joint task forces.

What distinguishes the DEA from a purely investigative agency is its role in the drug-scheduling system. The CSA sorts controlled substances into five schedules based on their potential for abuse, accepted medical use, and risk of dependence, with Schedule I carrying the most stringent controls and reserved for substances the law treats as having no currently accepted medical use. Under 21 U.S.C. § 811, the DEA administers the process for adding, removing, or reclassifying substances—ordinarily requiring a scientific and medical evaluation from the Department of Health and Human Services (HHS), public notice-and-comment rulemaking, and, when requested, an administrative hearing before an administrative law judge.

Those classifications regulate medicine and define criminal exposure. Under federal law, the penalties for manufacturing, distributing, or possessing a controlled substance are graded by schedule, with Schedule I and II offenses generally treated most severely. And that framework reaches well beyond federal court. Most states have modeled their own controlled-substances laws on the federal CSA, with many incorporating the federal schedules directly—often through provisions that automatically conform to federal rescheduling. Their criminal codes then grade offenses by schedule, so that possessing or selling a Schedule I or II substance is a more serious felony than an offense involving a lower-scheduled drug. Because state and local authorities prosecute most drug crimes in the United States, a single federal scheduling decision can shape criminal liability for far more people than the DEA itself will ever arrest. Marijuana is the conspicuous exception. Even as it has remained a Schedule I substance under federal law, most states have legalized it for medical or recreational use—inverting the usual pattern and leaving federal and state law openly at odds, a divergence that the 2026 federal rescheduling effort narrows but does not erase.

That scheduling is the mechanism at the heart of the recent marijuana rescheduling effort, and the clearest illustration of how the DEA’s power can be directed differently across administrations. The current chapter began in October 2022, when President Biden directed HHS and the DEA to review marijuana’s Schedule I status. HHS recommended a move to Schedule III in 2023, and the DEA issued a proposed rule to that effect in May 2024. The process then stalled, an administrative hearing was paused in early 2025 amid disputes over the proceedings, and the agency was left without an administrative law judge to resolve them until President Trump intervened with Executive Order 14370 in December 2025, directing the attorney general to complete the rulemaking as expeditiously as the law allows. As the Congressional Research Service has noted, a president cannot unilaterally reschedule a drug because the authority runs through the attorney general and the DEA.

On April 23, 2026, Acting Attorney General Todd Blanche issued a final order creating a two-tier framework: it moved FDA-approved marijuana products and marijuana sold under a qualifying state medical license from Schedule I to Schedule III, while leaving all other marijuana, including recreational adult-use products, in Schedule I. The order withdrew the stalled 2024 hearing and routed the broader question of rescheduling all marijuana into a new, expedited hearing set to begin June 29, 2026. The current situation captures the DEA’s distinctive position as it is the same agency that enforced marijuana’s Schedule I status for more than five decades is now the institution administering its partial reclassification.

Hiring and Training

The DEA maintains rigorous, competitive standards for its special agents. Applicants must generally:

• Be U.S. citizens, generally between the ages of 21 and 36 at the time of appointment;
• Hold a bachelor’s degree (or higher) or possess qualifying professional experience;
• Pass a multi-part selection process, including written assessments, a panel interview, and a physical task assessment;
• Clear a polygraph examination, drug test, medical and psychological evaluations, and a full background investigation;
• Obtain a security clearance.

Selected candidates attend the 14-week Basic Agent Training Program at the DEA Academy in Quantico, Virginia, which is one of the few federal agencies, alongside the FBI, to run its own academy rather than train at the shared federal centers. The residential program covers federal drug law, investigative and undercover techniques, surveillance, search-and-seizure law, firearms, defensive tactics, and physical fitness, and is followed by a field training program once agents reach their assigned offices.

The DEA operates under the same Use of Force Policy that governs other DOJ agencies. It applies the Graham v. Connor (1989) objective-reasonableness standard, meaning agents may use only the level of force a reasonable officer would consider necessary under the circumstances. The policy prohibits chokeholds and carotid restraints unless the deadly-force standard is met and requires de-escalation when feasible.

One detail underscores the theme running through this installment: the agency’s own pre-employment drug policy continues to treat recent marijuana use as disqualifying. Applicants generally cannot have used cannabis in any form within three years of applying, regardless of state law, and those seeking state licenses to cultivate or distribute it are deemed to have a conflict of interest with the DEA’s mission. Even as the agency administers marijuana’s partial reclassification, the drug remains federally controlled, and the DEA’s internal standards reflect that.

Concluding the Series

The DEA closes a series that began with a simple premise: federal law enforcement deserves to be understood on the basis of facts rather than headlines. Across these analyses—U.S. Customs and Border Protection (CBP), U.S. Immigration and Customs Enforcement (ICE), the FBI, the Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF), and the DEA—several throughlines emerged. Each agency draws its power from specific acts of Congress rather than any general law enforcement authority. The basis for that jurisdiction varies. The FBI, ATF and DEA follow the category of crime rather than any line on a map, while CBP and ICE exercise authorities in which geography, the border, ports of entry, and the zones in which they operate, play a central role. Each agency’s mission, however it is written, is interpreted and deployed differently from one administration to the next.

The DEA may illustrate that last point most vividly of all. The agency’s authority over drug scheduling is fixed in statute, yet the marijuana question shows how the same legal machinery can be pointed toward stricter enforcement in one era and toward loosening restrictions in another. Understanding where that authority comes from, and where its limits lie, is what allows a citizen to evaluate any given exercise of it.

As with every installment, the purpose here has not been to tell readers what to think about federal law enforcement agencies in the U.S., but to provide the factual foundation to think about them clearly. That foundation matters most precisely when these agencies are at the center of national debate.

bool(true)

bool(true)

string(3) "100"

This concludes the six-part series, Understanding Federal Law Enforcement in the United States.